glp-1 receptor agonist type 1 diabetes randomized trial Clinical efficacy results from clinical trials comparing different GLP-1 receptor agonists show promise

the 24 lawsuits brought by brand-name firms against generic competitors are either ongoing (n=14), were settled (n=5), were terminated for procedural reasons (n=2), or were decided in favor of the brand-name firm (n=3)

We estimate that people who are homozygous for the risk alleles at both the GLP1R and GIPR loci have a 14.8-fold increased odds (95% confidence interval [6.2, 35.8]) of tirzepatide-mediated vomiting, compared with those homozygous for the non-risk alleles

But certainly in patients who may have a greater level of obesity associated with their type 2 diabetes, perhaps initiating semaglutide before an SGLT2 inhibitor because of the weight benefit, the CV risk lowering, as well as the CKD benefit, may be appropriate. More screening needed Providers are hopeful the FLOW trial may raise greater awareness of CKD screening, particularly the measurement of UACR

Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D

Interestingly, ketogenic diets combined with intermittent fasting can mimic the biological effects of GLP-1-based medications

GLP-1 (glucagon-like peptide-1) receptor agonists are a newer class of medications that mimic a natural hormone your intestines release after eating